Propanalol Betacap TR 20 is a prescription cardiovascular formulation developed to support consistent blood pressure control and symptomatic relief in patients with hypertension and related conditions. Sun Pharmaceutical Industries produces this product to meet global demand for reliable, affordable beta-blocker therapy with controlled-release technology.
For clinicians and patients seeking long-acting beta-blocker options, understanding the profile, availability, and regulatory aspects of Propanalol Betacap TR 20 is essential for safe and effective use. The following sections provide structured insights into its specifications, market positioning, and practical considerations.
| Parameter | Specification | Unit | Reference |
|---|---|---|---|
| Active Ingredient | Propranolol | mg | Formulation component |
| Brand Name | Betacap TR 20 | — | Commercial identity |
| Release Technology | Extended/Controlled Release | — | Therapeutic duration |
| Typical Strength | 20 | mg | Common dosing unit |
| Manufacturer | Sun Pharmaceutical Industries | — | Global supplier |
Therapeutic Use and Clinical Profile
Propanalol Betacap TR 20 is indicated for the management of hypertension, angina pectoris, and certain arrhythmias where beta-blockade is clinically appropriate. By blocking beta-adrenergic receptors, propranolol reduces heart rate, myocardial contractility, and renin release, contributing to lower blood pressure and reduced myocardial oxygen demand.
Sun Pharmaceutical Industries formulates this product with a controlled-release matrix to sustain therapeutic plasma concentrations over an extended dosing interval. This approach may improve adherence and minimize peak-related side effects compared to immediate-release alternatives, provided the regimen aligns with labeled indications and patient-specific factors.
Manufacturing Standards and Regulatory Status
Quality Assurance by Sun Pharmaceutical
As a globally recognized pharmaceutical company, Sun Pharmaceutical Industries operates multiple compliant manufacturing sites that adhere to Good Manufacturing Practice (GMP) standards. Propanalol Betacap TR 20 undergoes rigorous quality control testing to ensure batch-to-batch consistency, potency, and safety.
Regulatory Approvals and Market Availability
The availability of Propanalol Betacap TR 20 varies by country, depending on local regulatory approvals and registration status. In regions where it is registered, it is typically supplied in prescription packs with detailed labeling regarding dosage, storage conditions, and required monitoring parameters.
Dosing, Administration, and Safety Considerations
Because Propanalol Betacap TR 20 delivers a sustained release of propranolol, it is usually administered once daily with or without food, as directed by a healthcare professional. The extended-release design helps maintain stable drug levels, but abrupt discontinuation can precipitate rebound tachycardia or hypertension, particularly in patients on chronic therapy.
Clinicians should assess renal and hepatic function, concomitant medications, and history of asthma or peripheral vascular disease before initiation. Regular follow-up, including blood pressure and heart rate measurement, supports optimal dose adjustment and early detection of adverse effects.
Market Position and Competitive Landscape
| Product | Manufacturer | Release Type | Typical Strength | Primary Indication |
|---|---|---|---|---|
| Propanalol Betacap TR 20 | Sun Pharmaceutical Industries | Extended Release | 20 mg | Hypertension, Angina |
| Brand Beta-Blocker X | Global Pharma | Extended Release | 40 mg | Hypertension, Arrhythmia |
| Generic Propranolol SA | Regional Laboratories | Sustained Release | 20–80 mg | Multiple cardiovascular conditions |
Key Takeaways and Practical Recommendations
- Propanalol Betacap TR 20 provides extended blood pressure control with once-daily dosing under medical supervision.
- Sun Pharmaceutical Industries ensures consistent quality through GMP-compliant manufacturing and regulatory compliance.
- Patients should avoid sudden discontinuation and report any new symptoms or medication changes to their clinician.
- Regular monitoring of cardiovascular parameters supports safe and effective long-term use of this beta-blocker.
- Understanding drug interaction profiles helps minimize risks and optimize therapeutic outcomes in diverse patient populations.
FAQ
Reader questions
What conditions is Propanalol Betacap TR 20 prescribed for?
It is primarily prescribed for hypertension and angina pectoris, and may be used off-label for certain arrhythmias and migraine prophylaxis under clinical guidance.
How does the extended-release formulation affect dosing frequency?
The controlled-release design allows once-daily dosing in many cases, supporting better adherence compared to multiple daily administrations of immediate-release propranolol.
Can this medication be stopped suddenly if I feel better?
No, abrupt discontinuation can lead to rebound tachycardia, hypertension, or ischemia. Any changes to therapy should be discussed with a healthcare provider.
Are there specific drug interactions to monitor while using Propanalol Betacap TR 20?
Yes, concurrent use with calcium channel blockers, antiarrhythmics, or certain antidepressants requires careful monitoring due to potential additive effects on heart rate and blood pressure.